Drug intelligence / Profile preview

SY-4835

Development stage: Phase 1
Lead developer: Shouyao Holdings
Modality: Small Molecules
Administration: Oral

Overview

SY-4835 is a WEE1 inhibitor being developed for the treatment of advanced solid tumors. It is administered orally as tablets and works by inhibiting the WEE1 kinase, which plays a crucial role in cell cycle regulation at the G2 checkpoint. By preventing the phosphorylation of CDK1, SY-4835 may force cancer cells with DNA damage to proceed through mitosis without proper repair, leading to mitotic catastrophe and cell death. The drug is currently in Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity.

Targets

WEE1 (WEE1 G2 checkpoint kinase)

Beyond the preview

Go deeper on SY-4835.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-4835.

Explore the full profile